Globus Medical INC Form 4 insider transactions

Globus Medical's CFO, Kyle Kline, was granted 20,909 stock options with an exercise price of $56.34, vesting over four years.

Director Davidar David D. of Globus Medical Inc. [GMED] reports the acquisition of 15,000 stock options on January 23, 2025, exercisable for Class A Common Stock.

Director John A. DeFord of Globus Medical Inc. reports the acquisition of stock options exercisable for 15,000 shares of Class A Common Stock.

Director Douglas Robert Andrew acquired 15,000 stock options in Globus Medical, Inc. on January 23, 2025, which will vest on January 1, 2026.

Kelly Huller, SVP, GC, and Corporate Secretary of Globus Medical Inc., reports the acquisition of stock options.

Director Dan Lemaitre of Globus Medical Inc. was granted stock options for 15,000 shares of Class A Common Stock on January 23, 2025.

Director Leslie V. Norwalk reports acquisition of 15,000 stock options in Globus Medical Inc. (GMED) on January 23, 2025.

Paul David C., Executive Chairman of Globus Medical, was granted 75,000 stock options on January 23, 2025, according to a Form 4 filing.

COO of Globus Medical, Keith W. Pfeil, reports acquisition of 60,000 stock options exercisable for Class A Common Stock.

Director Ann D. Rhoads of Globus Medical Inc. (GMED) was granted 15,000 stock options on January 23, 2025, exercisable for Class A Common Stock.

Globus Medical's CEO, Daniel T. Scavilla, was granted 140,000 stock options on January 23, 2025, according to a Form 4 filing with the SEC.

Director James R. Tobin acquired 15,000 stock options in Globus Medical Inc. on January 23, 2025, according to a Form 4 filing.

Director Dan Wolterman of Globus Medical Inc. [GMED] acquired stock options for 15,000 shares of Class A Common Stock on January 23, 2025.

Director Stephen T Zarrilli acquired 15,000 stock options in Globus Medical Inc. on January 23, 2025, according to a Form 4 filing.

Director Ann D. Rhoads sold 7,500 shares of Globus Medical Inc. (GMED) Class A Common Stock on February 28, 2025, at a price of $78.68 per share.

Keith W. Pfeil, COO and CFO of Globus Medical Inc., exercised stock options and sold shares of Class A Common Stock on January 10, 2025, according to a recent SEC Form 4 filing.

A Globus Medical executive, Kelly Huller, exercised stock options and sold shares on December 2, 2024, according to a recent SEC filing.

Globus Medical director Davidar David D sold a total of 39,990 Class A common shares across multiple transactions on November 21st and 22nd, 2024, under a pre-arranged 10b5-1 trading plan.

A Globus Medical director, Dan Lemaitre, exercised stock options and sold shares in multiple transactions on November 21st and 22nd, 2024.

Globus Medical CEO Daniel T. Scavilla exercised stock options and sold 130,000 shares of Class A Common Stock on November 21, 2024, under a pre-arranged 10b5-1 trading plan.

Globus Medical's Executive Chairman, David Paul, exercised stock options for 26,042 shares of Class A Common Stock at a price of $24.10 per share.

Globus Medical's CEO, Daniel Scavilla, exercised stock options and sold 60,000 shares of Class A Common Stock on November 6, 2024, according to a recent SEC filing.

Kelly Huller, SVP, GC, and Corporate Secretary of Globus Medical, exercised stock options and sold shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Kelly Huller, SVP, GC, and Corporate Secretary of Globus Medical, exercised stock options and sold 7,500 shares of Class A Common Stock on October 16, 2024.

Director Davidar D. Davidar of Globus Medical Inc. executed sales of Class A Common Stock totaling $3.75 million on October 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Ann Rhoads exercised stock options and sold shares of Globus Medical (GMED) on September 13, 2024.

Director Davidar D. Davidar exercised stock options and sold 25,000 shares of Globus Medical Inc. (GMED) Class A Common Stock on September 13, 2024.

Director Leslie V. Norwalk sold 1,000 shares of Globus Medical Inc. (GMED) Class A Common Stock at $70 per share on July 11, 2024, according to a Form 4 filing.

Director Dan Lemaitre exercised stock options and sold shares of Globus Medical Inc. on May 10, 2024.

Director Davidar D. Davidar sold 20,000 shares of Globus Medical Inc. (GMED) Class A Common Stock on May 8, 2024, at a price of $65 per share, according to a Form 4 filing with the SEC.